Tactile Systems Stock Price, News & Analysis

Tactile Systems Technology (Nasdaq: TCMD) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14, 2022, in New York City. The company's management will engage in a fireside chat on September 13 at 11:10 a.m. Eastern Time. Interested parties can access a live audio webcast through the company’s investor relations website, with an archive available for replay post-conference. Tactile Medical focuses on at-home therapies for chronic conditions like lymphedema and chronic pulmonary disease.

Tactile Systems Technology (TCMD) reported a 17% year-over-year revenue increase for Q2 2022, totaling $59.6 million. This growth was driven primarily by airway clearance product sales, which rose 96% from the previous year. Despite revenue growth, the company faced a net loss of $4.6 million compared to a net income of $1.3 million in Q2 2021, and operating expenses increased by 30%. The updated revenue guidance for 2022 is now set between $238 million and $242 million, reflecting an expected 14% to 16% growth.

Tactile Systems Technology (Nasdaq: TCMD) has announced the full market release of its new ComfortEase garments, enhancing the Flexitouch Plus system for lymphedema management. Developed from over 18,000 patient and therapist feedback, these garments aim to improve comfort, fit, and usability. Additionally, the company introduced the Kylee mobile app, assisting patients in health monitoring and symptom management. The app enables users to track their progress and engage with healthcare providers, reinforcing Tactile Medical's commitment to supporting patients with chronic conditions.

Tactile Systems Technology (Nasdaq: TCMD) will release its Q2 2022 financial results on August 1, 2022, after market close. The company specializes in medical devices for chronic diseases, providing at-home therapies for conditions like lymphedema and chronic venous insufficiency. A conference call will follow at 5:00 PM ET for discussion and a Q&A session. Interested parties can join by calling 877-407-3088 or via a live webcast on the investor relations website.

Tactile Systems Technology (Nasdaq: TCMD) announced a consensus statement highlighting the treatment of lymphedema, particularly secondary to chronic venous insufficiency (CVI). Published in Phlebology: The Journal of Venous Disease, the statement received endorsements from three independent professional societies. Key points include that pneumatic compression is recommended for lymphedema patients, and 92% of experts support its use. CEO Dan Reuvers emphasized the importance of addressing the estimated 20 million undiagnosed lymphedema cases in the U.S.

Tactile Systems Technology (Nasdaq: TCMD) will participate in the William Blair 42nd Annual Growth Stock Conference from June 6-9, 2022, at the Loews Chicago Hotel. Management will present to investors on June 7 at 1:20 p.m. Central Time, followed by a breakout session. A live audio webcast will be available on the company’s investor relations website, with a replay accessible after the conference.

Tactile Medical specializes in developing at-home therapies for chronic conditions like lymphedema and chronic pulmonary disease, aiming to improve patient care and reduce healthcare costs.

Tactile Systems Technology (Nasdaq: TCMD) reported a 12% increase in revenue for Q1 2022, totaling $48.0 million, up from $42.8 million in Q1 2021. Revenue included $7.3 million from airway clearance products, notably the AffloVest product line. However, the company faced significant challenges with an operating loss of $14.9 million and a net loss of $15.6 million, compared to losses of $4.1 million and $2.3 million respectively in Q1 2021. The company reaffirmed its 2022 revenue guidance of $235 million to $240 million, a growth of 13% to 15% year-over-year.

Avation Medical has appointed Darren Wennen as Chief Marketing Officer to lead marketing and sales for its novel wearable neuromodulation system targeting overactive bladder (OAB) and urge urinary incontinence (UUI). With a proven track record in the medical device field, Wennen previously held significant roles at Tactile Medical, driving sales over $200 million. The company's therapy aims to provide a non-invasive treatment option for the 42 million Americans suffering from OAB and UUI, currently in investigational use and not yet FDA cleared.

Tactile Systems Technology, Inc. (Nasdaq: TCMD) will release its first quarter fiscal 2022 financial results on May 2, 2022, after market close. A conference call to discuss the results is scheduled for 5:00 PM ET the same day, with dial-in options available for participants. Tactile Medical focuses on developing at-home therapies for chronic conditions, enhancing patient care and access to treatment. The company aims to improve patient quality of life while collaborating with clinicians to manage healthcare costs effectively.